Multiple Myeloma

In this MD Newsline exclusive interview with oncologist Dr. Onyemaechi Okolo, we discuss the high incidence and prevalence of multiple myeloma in the Black community. We also discuss how multiple myeloma presents in Black Americans. MD Newsline: Why is multiple myeloma so prevalent in the Black community?  Dr. Onyemaechi Okolo: “So, there is a genetic...

Among patients with multiple myeloma, elderly patients tend to experience worse outcomes. Patients who are very elderly or who experience comorbidities may not have certain treatment options offered to them secondary to clinician concern for treatment toxicity. This study aimed to analyze the survival disparity between younger and older patients with multiple myeloma to understand if...

Multiple myeloma (MM) develops from precursor states known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Disparities between Black and white patients exist at all stages of the disease. Black patients exhibit higher prevalence rates and a higher mortality rate. This article reviews the socioeconomic factors, genomic factors, and other factors...

Multiple myeloma is a form of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help fight infections by making antibodies that recognize and attack germs.    Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells.  Researchers found that...

More than three out of four patients with multiple myeloma that had unsuccessful therapy have been found to remain in remission more than seven months after treatment with a CAR T-cell therapy targeting two proteins that are frequently found on myeloma cells. Those experiencing sustained remissions include nine patients with a difficult-to-treat form of multiple...

Source: www.BloodJournal.com Compared with whites, African Americans and Hispanics receive treatment later and with higher associated costs (WASHINGTON, October 17, 2019) — Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances. The study found...